NCT00923221 Collection of Blood From Patients With Prostate Cancer
| NCT ID | NCT00923221 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Cancer Institute (NCI) |
| Condition | Cancer Of Prostate |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2007-02-28 |
| Primary Completion | — |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2007-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Background: * It is not fully understood why prostate cancer in some men becomes androgen-independent (no longer responds to anti-androgen medication), but genetics likely plays an important role. * Genes contain the hereditary information that is passed down from parents to children. Although everyone has the same set of genes, individuals can have different forms of the same gene. * Differences in genes may explain, at least in part, why some people develop a more aggressive form of prostate cancer than others. Objectives: -To obtain blood samples from patients with prostate cancer to try to identify gene differences associated with progression to the androgen independent state. Eligibility: -All participants participating in NCI prostate cancer protocols. Design: * Participants with prostate cancer are evaluated in the NCI s Medical Oncology Clinic. * Blood samples are collected at the initial visit or at follow-up visits. * DNA (genetic material) and white blood cells are extracted from these samples to be used for genotyping and establishment of cell lines. * Gene variations are correlated with prostate cancer prognosis and prognostic indicators.
Eligibility Criteria
* INCLUSION CRITERIA: Individuals 18 years of age and older are eligible. Individuals with a diagnosis of prostate cancer are eligible. EXCLUSION CRITERIA: Children are not eligible.
Contact & Investigator
William D Figg, Pharm.D.
PRINCIPAL INVESTIGATOR
National Cancer Institute (NCI)
Frequently Asked Questions
Who can join the NCT00923221 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Cancer Of Prostate. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00923221 currently recruiting?
Yes, NCT00923221 is actively recruiting participants. Contact the research team at pcartera@mail.nih.gov for enrollment information.
Where is the NCT00923221 trial being conducted?
This trial is being conducted at Bethesda, United States.
Who is sponsoring the NCT00923221 clinical trial?
NCT00923221 is sponsored by National Cancer Institute (NCI). The principal investigator is William D Figg, Pharm.D. at National Cancer Institute (NCI). The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.